skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study

Abstract

BackgroundRadioembolization induced liver disease (REILD) is a possible sequela of transarterial radioembolization (TARE), particularly in cases of whole-liver treatment. To mitigate this problem, the safety and efficacy of combined transarterial chemoembolization (TACE) and TARE were evaluated for patients with bilobar hepatocellular carcinoma (HCC).Materials and MethodsNineteen patients (mean age 60 years; range 27–82 years) treated for HCC between June 2012 and September 2014 were included in the analysis. Each patient was treated with combined TARE and TACE for bilobar HCC, with or without portal vein thrombosis. The hepatic lobe with large HCC was treated with TARE, and the other lobe with small HCC(s) was treated with TACE. Laboratory and clinical data were investigated to determine REILD occurrence. Survival data were analyzed to compare the treatment efficacy of alternative treatment modalities, including TACE and sequential TARE.ResultsAll patients underwent TARE for a dominant tumor in one lobe and TACE for small nodule(s) in the other lobe of the liver. The mean yttrium-90 microspheres used in TARE were 2.8 GBq (range; 1.0-3.5 GBq), and the mean doses of doxorubicin and iodized oil were 24.5 mg and 5.2 mL, respectively, for TACE. No statistical differences were noted between laboratory data measured before and after treatment, and no procedure-related major clinical complicationsmore » occurred. The median time-to-progression of patients was 10.0 months, and the median overall survival was 27.3 months.ConclusionCombined radioembolization and chemoembolization appears to be a safe and effective treatment modality for bilobar HCC.« less

Authors:
; ; ; ; ; ; ; ;  [1]; ;  [2]
  1. Yonsei University College of Medicine, Department of Radiology (Korea, Republic of)
  2. Yonsei University College of Medicine, Department of Internal Medicine, Institution of Gastroenterology (Korea, Republic of)
Publication Date:
OSTI Identifier:
22756194
Resource Type:
Journal Article
Journal Name:
Cardiovascular and Interventional Radiology
Additional Journal Information:
Journal Volume: 41; Journal Issue: 3; Other Information: Copyright (c) 2018 Springer Science+Business Media, LLC, part of Springer Nature and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE); Article Copyright (c) 2017 Springer Science+Business Media, LLC and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE); http://www.springer-ny.com; Country of input: International Atomic Energy Agency (IAEA); Journal ID: ISSN 0174-1551
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; HEPATOMAS; LIVER; PATIENTS; RADIOEMBOLIZATION; YTTRIUM 90

Citation Formats

Kwon, Joon Ho, Kim, Gyoung Min, E-mail: GYOUNGMIN@yuhs.ac, Han, Kichang, Won, Jong Yun, Kim, Man Deuk, Lee, Do Yun, Lee, Junhyung, Choi, Woosun, Kim, Yong Seek, Kim, Do Young, and Han, Kwang-Hyub. Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study. United States: N. p., 2018. Web. doi:10.1007/S00270-017-1826-7.
Kwon, Joon Ho, Kim, Gyoung Min, E-mail: GYOUNGMIN@yuhs.ac, Han, Kichang, Won, Jong Yun, Kim, Man Deuk, Lee, Do Yun, Lee, Junhyung, Choi, Woosun, Kim, Yong Seek, Kim, Do Young, & Han, Kwang-Hyub. Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study. United States. doi:10.1007/S00270-017-1826-7.
Kwon, Joon Ho, Kim, Gyoung Min, E-mail: GYOUNGMIN@yuhs.ac, Han, Kichang, Won, Jong Yun, Kim, Man Deuk, Lee, Do Yun, Lee, Junhyung, Choi, Woosun, Kim, Yong Seek, Kim, Do Young, and Han, Kwang-Hyub. Thu . "Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study". United States. doi:10.1007/S00270-017-1826-7.
@article{osti_22756194,
title = {Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study},
author = {Kwon, Joon Ho and Kim, Gyoung Min, E-mail: GYOUNGMIN@yuhs.ac and Han, Kichang and Won, Jong Yun and Kim, Man Deuk and Lee, Do Yun and Lee, Junhyung and Choi, Woosun and Kim, Yong Seek and Kim, Do Young and Han, Kwang-Hyub},
abstractNote = {BackgroundRadioembolization induced liver disease (REILD) is a possible sequela of transarterial radioembolization (TARE), particularly in cases of whole-liver treatment. To mitigate this problem, the safety and efficacy of combined transarterial chemoembolization (TACE) and TARE were evaluated for patients with bilobar hepatocellular carcinoma (HCC).Materials and MethodsNineteen patients (mean age 60 years; range 27–82 years) treated for HCC between June 2012 and September 2014 were included in the analysis. Each patient was treated with combined TARE and TACE for bilobar HCC, with or without portal vein thrombosis. The hepatic lobe with large HCC was treated with TARE, and the other lobe with small HCC(s) was treated with TACE. Laboratory and clinical data were investigated to determine REILD occurrence. Survival data were analyzed to compare the treatment efficacy of alternative treatment modalities, including TACE and sequential TARE.ResultsAll patients underwent TARE for a dominant tumor in one lobe and TACE for small nodule(s) in the other lobe of the liver. The mean yttrium-90 microspheres used in TARE were 2.8 GBq (range; 1.0-3.5 GBq), and the mean doses of doxorubicin and iodized oil were 24.5 mg and 5.2 mL, respectively, for TACE. No statistical differences were noted between laboratory data measured before and after treatment, and no procedure-related major clinical complications occurred. The median time-to-progression of patients was 10.0 months, and the median overall survival was 27.3 months.ConclusionCombined radioembolization and chemoembolization appears to be a safe and effective treatment modality for bilobar HCC.},
doi = {10.1007/S00270-017-1826-7},
journal = {Cardiovascular and Interventional Radiology},
issn = {0174-1551},
number = 3,
volume = 41,
place = {United States},
year = {2018},
month = {3}
}